Anti–Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular α-Particle Therapy of Cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Nuclear Medicine

• Publication date

  2014-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2967/jnumed.113.125476PMID 24337602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Measurement of the 225Ac half-life.

  2012cited by this paper
• Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium.

  2011cited by this paper
• MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy*

  2010cited by this paper
• Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.

  2010cited by this paper
• Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. I. Presentation and Validation of a Microdosimetric Model

  2009cited by this paper
• Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. II. Application of the Microdosimetric Model to Experimental Results

  2009cited by this paper
• Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases.

  2008cited by this paper
• Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.

  2008cited by this paper
• Surface-active liposomes for targeted cancer therapy.

  2007cited by this paper
• Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

  2007cited by this paper
• Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

  2006cited by this paper
• Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer.

  2005cited by this paper
• Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

  2005cited by this paper
• Pharmacokinetics of therapeutic monoclonal antibodies used in oncology.

  2005cited by this paper
• Antibody-directed targeting of the vasculature of solid tumors

  2004influential reference
• Preliminary Results of Nanopharmaceuticals Used in the Radioimmunotherapy of Ovarian Cancer

  2004cited by this paper
• Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion.

  2004cited by this paper
• Engineered liposomes for potential alpha-particle therapy of metastatic cancer.

  2004cited by this paper
• Engineered Liposomes for Potential α-Particle Therapy of Metastatic Cancer

  2004cited by this paper
• Design and synthesis of 225Ac radioimmunopharmaceuticals.

  2002cited by this paper
• Targeted therapy of cancer with radiolabeled antibodies.

  2002cited by this paper
• Prostate-specific membrane antigen directed selective thrombotic infarction of tumors.

  2002cited by this paper
• Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

  2002cited by this paper
• Laparoscopic Splenectomy in Patients with Normal-Sized Spleens versus Splenomegaly: Does Size Matter?

  2001cited by this paper
• An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

  2000cited by this paper
• An α-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer

  2000cited by this paper
• Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

  1999cited by this paper
• Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

  1999cited by this paper
• Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

  1998cited by this paper
• Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues

  1998cited by this paper
• Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.

  1997cited by this paper
• Durable remission after splenectomy for Waldenström's macroglobulinemia with massive splenomegaly in leukemic phase.

  1997cited by this paper
• Mechanisms of splenic clearance of blood cells and particles : towards development of new splenotropic agents

  1995cited by this paper
• A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells.

  1995cited by this paper
• Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.

  1994cited by this paper
• A model of cell inactivation by alpha-particle internal emitters.

  1993cited by this paper
• Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.

  1993cited by this paper
• What is the evidence that tumors are angiogenesis dependent?

  1990cited by this paper
• Radioimmunotherapy with alpha-particle-emitting immunoconjugates.

  1988cited by this paper
• A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy.

  1987cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper

• Aptamer–liposome targeted nanotherapeutics for cancer therapy: Bibliometric analysis, recent developments and future perspectives

  2026cites this paper
• Functionalization Strategies for the Delivery of Anticancer Agents: Advancing Tumor-Targeted Liposomal Systems for Cancer Therapy

  2026cites this paper
• Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project

  2025cites this paper
• Aptamers as a new frontier in targeted cancer therapy.

  2025cites this paper
• Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects

  2025cites this paper
• Aptamers as target-specific recognition elements in drug delivery.

  2025cites this paper
• Aptamers Targeting Immune Checkpoints for Tumor Immunotherapy

  2025cites this paper
• Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy

  2025cites this paper
• Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment

  2025cites this paper
• Carrier systems of radiopharmaceuticals and the application in cancer therapy

  2024cites this paper
• Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives

  2024cites this paper
• Novel Aptamer Strategies in Combating Bacterial Infections: From Diagnostics to Therapeutics

  2024cites this paper
• Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer

  2024influential citation
• Actinium-225 targeted alpha particle therapy for prostate cancer

  2024cites this paper
• Navigating The Prostate Cancer Frontier: A Bibliometric and Altmetric Analysis of [225Ac]Ac-PSMA Therapy.

  2024cites this paper
• Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

  2024cites this paper
• Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?

  2024cites this paper
• Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics

  2024cites this paper
• Optimal Indications of Radioimmunotherapy in Nuclear Medicine: A Mini-Review.

  2024cites this paper
• Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer

  2023cites this paper
• Review of current status of targeted alpha therapy in cancer treatment.

  2023cites this paper
• DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors

  2023cites this paper
• Biomolecule-functionalized nanoformulations for prostate cancer theranostics

  2022cites this paper
• What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review

  2022cites this paper
• Aptamers as Theragnostic Tools in Prostate Cancer

  2022cites this paper
• Theranostic Radiolabeled Nanomaterials for Molecular Imaging and potential Immunomodulation Effects

  2022cites this paper
• 225Ac-rHDL Nanoparticles: A Potential Agent for Targeted Alpha-Particle Therapy of Tumors Overexpressing SR-BI Proteins

  2022cites this paper
• Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer

  2021cites this paper
• Nanosystem functionalization strategies for prostate cancer treatment: a review

  2021cites this paper
• Radiolabelling of nanomaterials for medical imaging and therapy.

  2021cites this paper
• Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications

  2021cites this paper
• Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach

  2021cites this paper
• Obstacles and Recommendations for Clinical Translation of Nanoparticle System-Based Targeted Alpha-Particle Therapy

  2021cites this paper
• Nanotargeted radiopharmaceuticals for cancer theranostics

  2021cites this paper
• Facile fluorescent aptasensor using aggregation-induced emission luminogens for exosomal proteins profiling towards liquid biopsy.

  2020cites this paper
• Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

  2020cites this paper
• The Power of Phytochemicals Combination in Cancer Chemoprevention

  2020cites this paper
• Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma

  2020cites this paper
• Nanoparticles for Targeting of Prostate Cancer.

  2020cites this paper
• Nanoparticles in Targeted Alpha Therapy

  2020influential citation
• A platform for the generation of site-specific antibody-drug conjugates that allows for selective reduction of engineered cysteines.

  2020cites this paper
• Aptamers: Magic Bullet for Theranostic Applications

  2020cites this paper
• LIPOSOMAL DRUG DELIVERY SYSTEMS FOR PROSTATE CANCER THERAPY: AN UPDATED REVIEW

  2020influential citation
• Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target

  2020cites this paper
• Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy

  2020cites this paper
• Evolution of Peptide-Based Prostate-Specific Membrane Antigen (PSMA) Inhibitors: An Approach to Novel Prostate Cancer Therapeutics.

  2020cites this paper
• Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies

  2020cites this paper
• Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer

  2019cites this paper
• Aptamer-functionalized liposomes for targeted cancer therapy.

  2019cites this paper
• GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.

  2019cites this paper
• Review of Therapeutic Applications of Radiolabeled Functional Nanomaterials

  2019cites this paper
• Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine

  2019cites this paper
• Recent Advancements in aptamer-bioconjugates: Sharpening Stones for breast and prostate cancers targeting

  2019cites this paper
• Nanomaterials multifunctional behavior for enlighten cancer therapeutics.

  2019cites this paper
• Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer

  2019cites this paper
• Aptamers Chemistry: Chemical Modifications and Conjugation Strategies

  2019cites this paper
• Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).

  2018cites this paper
• Alpha particle spectroscopy using FNTD and SIM super‐resolution microscopy

  2018cites this paper
• Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer.

  2018cites this paper
• Value proposition of PSMA-targeted α–particle radioligand therapy in metastatic prostate cancer

  2018cites this paper
• Aptamer‐guided nanomedicines for anticancer drug delivery

  2018cites this paper
• Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

  2018cites this paper
• Aptamer‐based targeted therapy

  2018cites this paper
• Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

  2018cites this paper
• Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches

  2018cites this paper
• Fluorescent nuclear track detectors for alpha radiation microdosimetry

  2018cites this paper
• Invited Solicitation Actinium-225 for Targeted a Therapy : Coordination Chemistry and Current Chelation Approaches

  2018cites this paper
• Fluorescent Nuclear Track Detectors for Alpha Particle Measurement

  2018cites this paper
• Alpha radiation dosimetry using Fluorescent Nuclear Track Detectors

  2018cites this paper
• Synthesis of novel multivalent fluorescent inhibitors with high affinity to prostate cancer and their biological evaluation.

  2018cites this paper
• Characteristics of Ibritumomab as Radionuclide Therapy Agent

  2018cites this paper
• Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer.

  2018cites this paper
• Targeted and Nontargeted α-Particle Therapies.

  2018cites this paper
• Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

  2018cites this paper
• New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen

  2018cites this paper
• Chapter 2 Recent Advances in Tumor Targeting Approaches

  2018cites this paper
• Nanoparticles for Radionuclide Imaging and Therapy: Principles

  2017cites this paper
• Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy.

  2017cites this paper
• Docetaxel-loaded solid lipid nanoparticles: a novel drug delivery system

  2017cites this paper
• Alpha-particle radiotherapy: For large solid tumors diffusion trumps targeting.

  2017cites this paper
• Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer.

  2017cites this paper
• 213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts

  2017cites this paper
• Anti-Prostate Cancer Activity of 8-Hydroxyquinoline-2-Carboxaldehyde–Thiosemicarbazide Copper Complexes by Fluorescent Microscopic Imaging

  2017cites this paper
• Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model

  2017cites this paper
• Techniques for Loading Technetium-99m and Rhenium-186/188 Radionuclides into Preformed Liposomes for Diagnostic Imaging and Radionuclide Therapy.

  2017cites this paper
• Liposomes

  2017cites this paper
• Radiolabelled Polymeric Materials for Imaging and Treatment of Cancer: Quo Vadis?

  2017cites this paper
• Radionuclide therapy using 131I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression

  2016cites this paper
• Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

  2016cites this paper
• Aptamers as smart ligands for nano-carriers targeting

  2016cites this paper
• The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease

  2016influential citation
• Aptamers as radiopharmaceuticals for nuclear imaging and therapy.

  2016cites this paper
• Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.

  2016cites this paper
• Molecular Imaging of Prostate Cancer.

  2016cites this paper
• Biodistribution of [68Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions

  2016cites this paper
• PSMA-Specific Ligands in Prostate Cancer Diagnosis and Therapy

  2016cites this paper
• Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer

  2016cites this paper
• Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues

  2015cites this paper
• Recent Advances in Tumor Targeting Approaches

  2015cites this paper
• Applications of aptamers in targeted imaging: state of the art.

  2015cites this paper